Latest articles and price-sensitive announcements with AI sentiment classification.
Cap Raise Crucible has dissected $700m in ASX raisings, led by L1 Global’s $480m haul, as brokers’ fees and options faced scrutiny and punters pocketed big gains or suffered double-digit losses.
This fortnight’s edition of Cap Raise Crucible has tracked $2.7B thundering through the ASX capital-raising machine, topped by NEXTDC’s monster $1.1 billion UBS-managed convertible note.
Echo IQ’s FDA setback has pushed back the timeline for EchoSolv HF, leaving the company to work through its next ... Read More The post Dr Boreham’s Crucible: Time is money as Echo IQ’s FDA setback winds back the clock appeared first on Stockhead.
The Cap Raise Crucible saw ASX cheque books wide open with over 35 raisings chasing $687.5M, led by big mining books. Canaccord was at the pointy end with nine deals worth $380M.
Amplia is the latest biotech to hedge its bets beyond its original remit and this month inked a collaboration with ... Read More The post Dr Boreham’s Crucible: Diversification has seen Amplia make ‘fashion statement’ appeared first on Stockhead.
While CT VQ imaging has turned heads, 4D Medical believes that CTPA represents an opportunity that is five times bigger. ... Read More The post Dr Boreham’s Crucible: 4D Medical gets wind of something big with CTPA appeared first on Stockhead.
Australia’s busiest capital raising period of the year delivered more than 60 plus ASX transactions as Australia’s brokers worked the room to extract over $1b in fresh capital for their ASX listed clients.
Back on the boards after its wet AMD setback, Opthea is pinning its hopes on a rare lung disease and ... Read More The post Dr Boreham’s Crucible: Opthea seeks a second act with rare lung disease program appeared first on Stockhead.
Formerly Pharmaxis, Syntara has reinvented itself more than once. With multiple clinical readouts approaching, the company hopes its next metamorphosis ... Read More The post Dr Boreham’s Crucible: Syntara seeks its latest transformation appeared first on Stockhead.
Quarterly revenue improvement points to burns and wound specialist Avita Medical being back on track, according to US-based CEO Cary ... Read More The post Dr Boreham’s Crucible: Avita Medical “back on track” … this time appeared first on Stockhead.
Racura believes its reworked cancer-fighting and cardio-protective agent bisantrene will be a catalyst to push share prices forward. ... Read More The post Dr Boreham’s Crucible: A reinvented Racura on the path to commercialisation appeared first on Stockhead.
Daybue turned Neuren into a biotech heavyweight. Now investors want to know whether the company’s next wave of rare disease ... Read More The post Dr Boreham’s Crucible: Neuren looks beyond Rett as Daybue royalties surge appeared first on Stockhead.
Artrya’s FDA-cleared AI heart imaging tools are now reimbursable in the US, targeting one of healthcare’s deadliest blind spots: hidden ... Read More The post Dr Boreham’s Crucible: Artrya bets on AI to outsmart heart disease appeared first on Stockhead.
Cochlear’s biggest woe in an earnings downgrade relates to developed markets – notably the US which accounts for more than ... Read More The post Dr Boreham’s Crucible: Cochlear’s rout a case of the punishment exceeding the crime appeared first on Stockhead.
A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read More The post Dr Boreham’s Crucible: CSL’s tough diagnosis appeared first on Stockhead.
Stockhead